TD Asset Management Inc Has $2.76 Million Position in Krystal Biotech, Inc. $KRYS

Key Points

• TD Asset Management Inc reduced its position in Krystal Biotech by 50.1% in the 2nd quarter, owning approximately $2.76 million worth of shares after selling 20,188 shares.
• Analysts have mixed opinions on Krystal Biotech, with Citigroup lowering its price target from $176.00 to $166.00, while Bank of America raised it to $255.00, indicating a consensus rating of "Moderate Buy."
• The stock of Krystal Biotech opened at $190.78, down 2.6%, with a market capitalization of $5.52 billion and a twelve-month high of $207.84.

TD Asset Management Inc reduced its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 50.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,080 shares of the company's stock after selling 20,188 shares during the period. TD Asset Management Inc owned approximately 0.07% of Krystal Biotech worth $2,760,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. Brooklyn Investment Group increased its stake in Krystal Biotech by 291.7% during the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company's stock worth $25,000 after acquiring an additional 105 shares during the period. Twin Tree Management LP bought a new position in Krystal Biotech during the 1st quarter worth $29,000. Smartleaf Asset Management LLC increased its stake in Krystal Biotech by 128.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 315 shares of the company's stock worth $58,000 after acquiring an additional 177 shares during the period. BI Asset Management Fondsmaeglerselskab A S bought a new position in Krystal Biotech during the 1st quarter worth $74,000. Finally, GAMMA Investing LLC increased its stake in Krystal Biotech by 179.3% during the 1st quarter. GAMMA Investing LLC now owns 673 shares of the company's stock worth $121,000 after acquiring an additional 432 shares during the period. 86.29% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Citigroup restated a "neutral" rating and set a $166.00 price objective (down previously from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Weiss Ratings reissued a "hold (c)" rating on shares of Krystal Biotech in a report on Wednesday, October 8th. Guggenheim set a $224.00 price target on Krystal Biotech and gave the stock a "buy" rating in a report on Friday. Chardan Capital lowered their price target on Krystal Biotech from $219.00 to $216.00 and set a "buy" rating for the company in a report on Friday, August 22nd. Finally, Bank of America boosted their price target on Krystal Biotech from $182.00 to $255.00 and gave the stock a "buy" rating in a report on Friday, October 17th. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Krystal Biotech currently has a consensus rating of "Moderate Buy" and a consensus price target of $223.00.

Krystal Biotech Stock Down 2.6%

Shares of KRYS stock opened at $190.78 on Wednesday. The firm has a market capitalization of $5.52 billion, a P/E ratio of 38.78 and a beta of 0.64. Krystal Biotech, Inc. has a twelve month low of $122.80 and a twelve month high of $207.84. The stock's fifty day simple moving average is $162.81 and its 200 day simple moving average is $151.55.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, topping analysts' consensus estimates of $1.08 by $0.21. The business had revenue of $96.04 million for the quarter, compared to analyst estimates of $95.42 million. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%. As a group, equities research analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.